Immuneering (IMRX)

• Market cap: $327M
• 1 day: 5.73%
• 5 days: 4.01%
• 1 month: 137.43%
• 3 months: 250.63%
• 6 months: 394.64%
• Year to date: 276.02%
• 1 year: 189.55%
• 5 years: -52.76%
• 10 years: -52.76%
• Sector: Healthcare
• Industry: Biotechnology

About: Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Employees: 54

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

89% more capital invested

Capital invested by funds: $6.84M [Q1] → $12.9M (+$6.07M) [Q2]

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

11% more funds holding

Funds holding: 35 [Q1] → 39 (+4) [Q2]

1.89% less ownership

Funds ownership: 12.53% [Q1] → 10.64% (-1.89%) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10
• Avg. target: $11.33
• High target: $13

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Needham Ami Fadia	$11	Buy Maintained	15 Sep 2025
Chardan Capital Geulah Livshits	$13	Buy Maintained	14 Aug 2025
Mizuho Graig Suvannavejh	$10	Outperform Maintained	18 Jun 2025